公开(公告)号：WO2016004045A1

公开(公告)日：2016-01-07

申请号：PCT/US2015/038565

申请日：2015-06-30

Applicant: ACADEMIA SINICA ,  LEE, Wen-hwa

Inventor： LEE, Wen-hwa ,  SHEW, Jin-yuh ,  MA, Che ,  CHEN, Chia-lin ,  LEE, Wen-hsin ,  HUANG, Chun-kai ,  WU, Heng-hsiung

IPC: A61K31/713 ,  A61K39/395

CPC classification number: C07K16/244 ,  A61K31/713 ,  A61K38/20 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K14/7155 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2320/31

Abstract: Methods and compositions for treatment and therapy of cancer are provided. Specifically, antagonists specific for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B are provided. Potent neutralizing antibodies specific for IL-17RB and methods for their manufacture and use are disclosed. The invention also relates to antisense, RNAi and shRNA compositions for the prevention and treatment of cancer, in particular breast cancer and pancreatic cancer.

Abstract translation: 提供了治疗和治疗癌症的方法和组合物。 具体而言，提供对白细胞介素-17受体B（IL-17RB）及其配体IL-17B特异性的拮抗剂。 公开了对IL-17RB特异性的强中和抗体及其制造和使用方法。 本发明还涉及用于预防和治疗癌症，特别是乳腺癌和胰腺癌的反义RNAi和shRNA组合物。

公开(公告)号：WO2015184009A1

公开(公告)日：2015-12-03

申请号：PCT/US2015/032745

申请日：2015-05-27

Applicant: ACADEMIA SINICA ,  WONG, Chi-Huey

Inventor： WONG, Chi-Huey ,  WU, Chung-Yi ,  MA, Che

IPC: C07K16/28

CPC classification number: C12P19/14 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1018 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C12N9/24 ,  C12Y302/01 ,  C12Y302/01051 ,  Y02A50/412 ,  Y02A50/466

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia 2 (α2-6)Gal 2 GlcNAc 2 Man 3 GlcNAc 2 . The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Abstract translation: 本公开涉及包含糖工程化Fc区的糖蛋白，特别是单克隆抗体，其中所述Fc区包含具有Sia2（α2-6）Gal2GlcNAc2Man3GlcNAc2结构的优化的N-聚糖。 相对于包含野生型Fc区域的可比较的单克隆抗体，糖工程化Fc区域以更高的亲和力结合FcγRIIA或FcγRIIIA。 本发明的单克隆抗体特别可用于预防，治疗或改善与需要由FcγR介导的效应细胞功能（例如，ADCC）增强的功效的疾病，病症或感染相关的一种或多种症状，例如， 癌症，自身免疫性，感染性疾病，以及提高其作用由ADCC介导的治疗性抗体的治疗功效。

公开(公告)号：WO2015184008A1

公开(公告)日：2015-12-03

申请号：PCT/US2015/032744

申请日：2015-05-27

Applicant: ACADEMIA SINICA ,  WONG, Chi-Huey

Inventor： WONG, Chi-Huey ,  TSAI, Tsung-I

IPC: C12N9/24

CPC classification number: C12P19/14 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1018 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C12N9/24 ,  C12Y302/01 ,  C12Y302/01051 ,  Y02A50/412 ,  Y02A50/466

Abstract: The present disclosure relates to an a-fucosidase having a-(1,2), a-(1,3), a-(1,4), and a-(1,6) fucosidase activity. The present disclosure also relates to the compositions comprising the α-fucosidase, and the methods of producing and using the α-fucosidase in cleaving a-(1,2), a-(1,3), a-(1,4), and/or a-(1,6)-linked fucoses in the glycoconjugates. Accordingly, the present invention provides the compositions and methods for the improved enzymatic hydrolysis of fucose in vitro. In particular, the present invention is useful for the efficient cleavage of core fucose in native glycoproteins without denaturation or functional deterioration of glycoproteins. The compositions and methods of the invention can facilitate the Fc glycoengineering of Fc fusion proteins or antibodies, such as therapeutic antibodies.

Abstract translation: 本公开涉及具有 - （1,2），α-（1,3），α-（1,4）和a-（1,6）岩藻糖苷酶活性的α-岩藻糖苷酶。 本公开还涉及包含α-岩藻糖苷酶的组合物，以及α-裂解酶（α），α-（1），（a） ，和/或a-（1,6）连接的岩藻糖。 因此，本发明提供了在体外改进岩藻糖的酶水解的组合物和方法。 特别地，本发明可有效地切割天然糖蛋白中的核心岩藻糖而不变性或糖蛋白的功能退化。 本发明的组合物和方法可以促进Fc融合蛋白或抗体（例如治疗性抗体）的糖糖工程化。

公开(公告)号：WO2015153816A2

公开(公告)日：2015-10-08

申请号：PCT/US2015/023956

申请日：2015-04-01

Applicant: ACADEMIA SINICA ,  CELLMAX, LTD. ,  CHANG, Ying-Chih

Inventor： CHANG, Ying-Chih ,  LAI, Jr-Ming ,  WU, Jen-Chia ,  CHEN, Huai-Lu ,  SHAO, Hung-Jen ,  LU, Si-Hong ,  HUNG, Tsung-Fu ,  HSIEH, Huangpin, Ben

IPC: G01N33/574

CPC classification number: G01N33/57492 ,  B01L3/502769 ,  B01L2200/0673 ,  B01L2300/0681 ,  B01L2300/0816 ,  B01L2400/0406 ,  B01L2400/0487 ,  G01N33/54366

Abstract: The disclosure provides for compositions and methods of making and using a foam composition and its utility in clinical applications.

Abstract translation: 本公开提供了制备和使用泡沫组合物的组合物和方法及其在临床应用中的应用。

公开(公告)号：WO2015134411A1

公开(公告)日：2015-09-11

申请号：PCT/US2015/018365

申请日：2015-03-02

Applicant: ACADEMIA SINICA ,  KAOHSIUNG MEDICAL UNIVERSITY ,  ROFFLER, Steven R.

Inventor： ROFFLER, Steven R. ,  CHENG, Tien-Lu ,  KAO, Chien-Han ,  CHEN, Bing-Mae ,  SU, Yu-Cheng ,  TUNG, Hsin-Yi

IPC: C07K16/46 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00

CPC classification number: A61K47/48746 ,  A61K47/6879 ,  A61K47/6897 ,  A61K49/0002 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/32 ,  C07K16/44 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/73

Abstract: Disclosed herein is a bi-specific antibody that specifically directs a therapeutic agent to a cancer cell by targeting a tumor antigen of the cancer cell, and thereby suppresses the growth of the cancer or blocking the invasion or metastasis of the cancer. The bi-specific antibody of the present disclosure includes a first antigen binding site that binds to polyethylene glycol (PEG); and a second antigen binding site that binds to a target ligand, such as a tumor antigen.

Abstract translation: 本文公开了通过靶向癌细胞的肿瘤抗原来特异性地将治疗剂引导至癌细胞的双特异性抗体，从而抑制癌症的生长或阻断癌症的侵袭或转移。 本公开的双特异性抗体包括结合聚乙二醇（PEG）的第一抗原结合位点; 以及结合靶配体例如肿瘤抗原的第二抗原结合位点。

公开(公告)号：WO2015116537A9

公开(公告)日：2015-08-06

申请号：PCT/US2015/012914

申请日：2015-01-26

Applicant: ACADEMIA SINICA ,  LIANG, Chi-Ming

Inventor： LI, Tsung-Lin ,  LYU, Syue-Yi ,  LIU, Yu-Chen ,  CHANG, Chin-Yuan

IPC: C07K9/00

Abstract: Described herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting bacterial growth. Methods of using the compounds for treating and/or preventing bacterial infection as well as methods of preparing the compounds are also described.

公开(公告)号：WO2015026484A9

公开(公告)日：2015-04-16

申请号：PCT/US2014048325

申请日：2014-07-26

Applicant: ACADEMIA SINICA ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  HSU HSIEN-YEH ,  LIAO SHIH-FEN ,  LIANG CHI-HUI

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  HSU HSIEN-YEH ,  LIAO SHIH-FEN ,  LIANG CHI-HUI

IPC: A61K31/715 ,  A61K31/736 ,  A61K36/074

CPC classification number: A61K39/0002 ,  A61K36/074 ,  A61K39/0011 ,  A61K2039/55572 ,  A61K2039/575

Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer comprising FMS, the fucose-enriched polysaccharide fraction from Reishi F3, are provided. Compositions comprise fucose-enriched Reishi polysaccharide fraction (FMS) MW = ~35kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-a-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain. Immunogenic compositions comprising glycolipid adjuvants are provided. Antibodies generated by immunogenic compositions disclosed herein bind cancer cells comprising antigens Globo H, Globo H, Gb3, Gb4, Gb5 (SSEA-3) and SSEA-4 on the cell surface.

Abstract translation: 提供免疫原性组合物，癌症疫苗和治疗癌症的方法，其包括FMS，来自Reishi F3的岩藻糖富集的多糖部分。 组合物包含岩藻糖富集的赖斯多糖级分（FMS）MW =〜35kDa，其中通过来自Reishi F3的大小排阻色谱分离FMS，并且FMS包含主要选自1,4-甘露聚糖和1,6 α-半乳聚糖，其中所述主链与含末端岩藻糖的侧链连接。 提供包含糖脂佐剂的免疫原性组合物。 由本文公开的免疫原性组合物产生的抗体结合细胞表面上包含抗原Globo H，Globo H，Gb 3，Gb 4，Gb 5（SSEA-3）和SSEA-4的癌细胞。

公开(公告)号：WO2015042435A1

公开(公告)日：2015-03-26

申请号：PCT/US2014/056611

申请日：2014-09-19

Applicant: ACADEMIA SINICA ,  SHIH, Chiaho ,  HUANG, Jyun-Yuan

Inventor： SHIH, Chiaho ,  HUANG, Jyun-Yuan

IPC: A61K48/00 ,  A61P3/10 ,  A61P3/00

CPC classification number: C12N15/1131 ,  A61K31/7088 ,  A61K45/06 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/113 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2730/10111

Abstract: Methods of regulating PGC1α and/or ΡGC1β, or treating diseases associated with PGC1α and/or ΡGC1β using a miR-130a RNA, miR-130b RNA, or a combination thereof, or using an antagomiR of miR-130a, an antagomiR of miR-130b, or both, which can be in the form of microRNA sponge or a locked nucleic acid (LNA).

Abstract translation: 调节PGC1α和/或Rgr; GC1 / bgr的方法，或治疗与PGC1α和/或Rgr; GC1和bgr相关的疾病; 使用miR-130a RNA，miR-130b RNA或其组合，或使用miR-130a的antagomiR，miR-130b的antagomiR或两者，其可以是微RNA海绵或锁定核酸的形式 （LNA）。

公开(公告)号：WO2014124047A4

公开(公告)日：2014-10-02

申请号：PCT/US2014014938

申请日：2014-02-05

Applicant: ACADEMIA SINICA ,  LIANG CHI MING

Inventor： SHIH CHIAHO ,  CHEN HENG-LI ,  SU PEI-YI

IPC: A01N37/18 ,  A61K39/29 ,  A61P31/04

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/12 ,  A61K39/292 ,  C12N7/00 ,  C12N2730/10133 ,  C12N2730/10134

Abstract: A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.

Abstract translation: 公开了用于杀死和/或抑制有需要的受试者中的微生物的生长和/或增殖或用于治疗受到微生物感染的受试者的药物组合物。 所述组合物包含：（a）有效量的分离的肽，其中所述肽包含乙型肝炎病毒核心蛋白（HBc）的富含精氨酸的羧基末端区域并显示出抗微生物活性; 和（b）药学上可接受的载体。 肽表现出对革兰氏阴性细菌，革兰氏阳性菌和/或真菌的活性。

公开(公告)号：WO2014109834A1

公开(公告)日：2014-07-17

申请号：PCT/US2013/071340

申请日：2013-11-21

Applicant: ACADEMIA SINICA ,  HO, Tuan-Hua, David

Inventor： HO, Tuan-Hua, David ,  YU, Su-May ,  CHEN, Yi-Shih ,  LO, Shuen-Fang

IPC: C12N15/29

CPC classification number: C12N15/8261 ,  C07K14/415 ,  C12N15/8271 ,  C12N15/8293 ,  Y02A40/146

Abstract: The present invention relates to a method for enhancing root growth of a plant by introducing a polynucleotide encoding late embryogenesis abundant protein, group 3 (LEA3) into the plant. Plant root architecture is essential for its functions in water and nutrient uptake, anchorage and interactions with microbes in the soil.

Abstract translation: 本发明涉及通过将编码晚期胚胎发生丰富蛋白质第3组（LEA3）的多核苷酸引入植物来提高植物根系生长的方法。 植物根系结构对于其在水中的功能和养分吸收，锚定和与土壤中微生物的相互作用至关重要。